Efficacy News and Research

RSS

ImStem successfully treats animal model of multiple sclerosis using hESC

ImStem Biotechnology, Inc. (ImStem) announced today it has successfully treated an animal model of multiple sclerosis (MS) using human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs), called hES-MSCs.

6 Jun 2014

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK.

6 Jun 2014

MolecularHealth launches innovative oncology program for employers

MolecularHealth announced today the official launch of MolecularHealth COPE (Corporate Oncology Program for Employers), powered by its cancer treatment decision support offering, TreatmentMAP.

6 Jun 2014

Study offers clues to best long-acting injectable antipsychotic use

Findings from the PROACTIVE study suggest why the benefits of long-acting injectable second-generation antipsychotics may be difficult to detect in a clinical trial.

5 Jun 2014

CBO to stop scoring some parts of the health law

The congressional budget analysts announce that they will continue to track the financial impact of the marketplaces and the Medicaid expansion program, but not some of the other smaller changes made under the law. Meanwhile, a new strategy for employers who provide health care is coming under scrutiny.

5 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962.

5 Jun 2014

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics, a privately held company dedicated to bringing new anti-cancer therapies to market, announced today (June 4) that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

5 Jun 2014

$SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus$

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).

5 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Thermo Fisher, Cellectis sign agreements on TALEN gene editing technology

Cellectis, a leader of engineered CART cell therapies, and Thermo Fisher Scientific announced today that they have entered into a series of agreements covering the uses of TAL nucleases under the brand name TALEN™.

5 Jun 2014

Study calls for more randomized trials on e-cigarettes

E-cigarettes are a potential smoking cessation aid and they may also be able to lower the risk of nicotine dependency in high-risk groups. The available scientific evidence, however, remains insufficient.

5 Jun 2014

Discovery of IDE may lead to new treatment approaches for diabetes

The discovery of an inhibitor of the Insulin Degrading Enzyme (IDE), a protein responsible for the susceptibility of diabetes because it destroys insulin in the body, may lead to new treatment approaches for diabetes.

5 Jun 2014

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

A study published in today's New England Journal of Medicine reports that the antibiotic dalbavancin is as effective as vancomycin, the current standard-of-care antibiotic used to treat serious bacterial skin and skin-structure infections.

5 Jun 2014

CenterVue's next generation Macular Integrity Assessment receives FDA clearance

CenterVue, Inc., a leader in the design and manufacture of highly automated medical devices for the diagnosis and management of ocular pathologies, today announced FDA 510(k) clearance has been granted for the company's next generation Macular Integrity Assessment (MAIA).

4 Jun 2014

Comparative study shows ultrasonic Bonescalpel makes spine surgery safe, efficient

Misonix, Inc., an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced that Dr. Ajay Krishnan of the prestigious Stavya Spine Hospital and Research Center in India concluded after a comparative study in 100 consecutive patients that the BoneScalpel is better than conventional methods in terms of safety and efficacy as it reduces the number of dural tears and neurological deficit, reduces blood loss and shortens operating time.

4 Jun 2014

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

4 Jun 2014

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

4 Jun 2014

NeuroVive extends collaboration with Hospices Civils de Lyon

NeuroVive is extending its collaboration with Hospices Civils de Lyon (HCL) and Professor Ovize, which broadens the scope of NeuroVive's cardiovascular business area and creates the right conditions for the company to retain its leading position in mitochondrial medicine.

4 Jun 2014

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today presented preclinical results showing that its lead development compound THR-184 can effectively protect against loss of kidney function following acute ischemic injury in rat.

4 Jun 2014

Efficacy News and Research

ImStem successfully treats animal model of multiple sclerosis using hESC

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

MolecularHealth launches innovative oncology program for employers

Study offers clues to best long-acting injectable antipsychotic use

CBO to stop scoring some parts of the health law

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Thermo Fisher, Cellectis sign agreements on TALEN gene editing technology

Study calls for more randomized trials on e-cigarettes

Discovery of IDE may lead to new treatment approaches for diabetes

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

CenterVue's next generation Macular Integrity Assessment receives FDA clearance

Comparative study shows ultrasonic Bonescalpel makes spine surgery safe, efficient

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

NeuroVive extends collaboration with Hospices Civils de Lyon

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News